dm+d
Unassigned
New Medicines
Atherosclerosis
Information
New molecular entity
Resverlogix Corp
Resverlogix Corp
Development and Regulatory status
None
Phase III Clinical Trials
Phase III Clinical Trials
Jun 18: Resverlogix received confirmation from the US FDA that the phase III BETonMACE study, s likely to support the filing and approval of a New Drug Application (NDA) [11]
Category
BET-protein inhibitor, facilitates endogenous ApoA-I production and raises HDL levels
Atherosclerosis usually manifests in later life, but its early phases are present in teenagers and young adults. [2]
Atherosclerosis
Oral